Inhibition of sepsis-induced inflammatory response by β1-adrenergic antagonists

Journal of Trauma and Acute Care Surgery

Volumn 76, Issue 2, 2014, Pages 320-328

  Ibrahim Zada, Irada ^a   Rhee, Peter ^a   Gomez, Christopher T ^a   Weller, John ^a   Friese, Randall S ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

A adrenergic antagonists; gene expression; mortality; mouse; sepsis

Indexed keywords

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; BRCA1 PROTEIN; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; KAPLAN-MEIER ESTIMATE; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; NF-KAPPA B P50 SUBUNIT; PROPANOLAMINES; RANDOM ALLOCATION; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE VALUES; RNA; SEPSIS; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84894158692     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000000113     Document Type: Article

References (38)

1. Chalupka AN, Talmor D. The economics of sepsis. Crit Care Clin. 2012; 28(1):57-76, vi.
2. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005; 365(9453):63-78.
3. Novotny NM, Lahm T, Markel TA, Crisostomo PR, Wang M, Wang Y, Ray R, Tan J, Al-Azzawi D, Meldrum DR. beta-Blockers in sepsis: reexamining the evidence. Shock. 2009;31(2):113-119.
4. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32(3):858-873.
5. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296-327.
6. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and metaanalysis. BMJ. 2004;329(7464):480.
7. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997;336(13): 912-918.
8. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov. 2003;2(5):391-405.
9. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709.
10. Rudiger A, Singer M. The heart in sepsis: from basic mechanisms to clinical management. Curr Vasc Pharmacol. 2013;11(2):187-195.
11. Macchia A, Romero M, Comignani PD, Mariani J, D'Ettorre A, Prini N, Santopinto M, Tognoni G. Previous prescription of A-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit Care Med. 2012;40(10):2768-2772.
12. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med. 1996; 335(23):1713-1720.
13. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999;341(24):1789- 1794.
14. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-225.
15. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, V tovec J, Aldershvile J, et al. Effects of controlledrelease metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF).MERIT-HF Study Group. JAMA. 2000;283(10):1295-1302.
16. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342(8885): 1441-1446.
17. Friese RS, Barber R, McBride D, Bender J, Gentilello LM. Could Beta blockade improve outcome after injury by modulating inflammatory profiles? J Trauma. 2008;64(4):1061-1068.
18. Kubon C, Mistry NB, Grundvold I, Halvorsen S, Kjeldsen SE, Westheim AS. The role of beta-blockers in the treatment of chronic heart failure. Trends Pharmacol Sci. 2011;32(4):206-212.
19. Zaugg M, Schaub MC, Pasch T, Spahn DR. Modulation of beta-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action. Br J Anaesth. 2002;88(1):101-123.
20. Gilbert EM, Abraham WT, Olsen S, Hattler B,White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94(11):2817-2825.
21. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79(3):483-490.
22. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, Harken AH. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med. 1999;27(7): 1309-1318.
23. de Montmollin E, Aboab J, Mansart A, Annane D. Bench-to-bedside review: beta-adrenergic modulation in sepsis. Crit Care. 2009;13(5):230.
24. Suzuki T, Morisaki H, Serita R, Yamamoto M, Kotake Y, Ishizaka A, Takeda J. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med. 2005;33(10):2294-2301.
25. Ackland GL, Yao ST, Rudiger A, Dyson A, Stidwill R, Poputnikov D, Singer M, Gourine AV. Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1-adrenoceptor blockade in severe sepsis in rats. Crit Care Med. 2010;38(2):388-394.
26. Ha YM, Ham SA, Kim YM, Lee YS, Kim HJ, Seo HG, Lee JH, Park MK, Chang KC. A1-adrenergic receptor-mediated HO-1 induction, via PI3K and p38 MAPK, by isoproterenol in RAW 264.7 cells leads to inhibition of HMGB1 release in LPS-activated RAW 264.7 cells and increases in survival rate of CLP-induced septic mice. Biochem Pharmacol. 2011; 82(7):769-777.
27. Walker-Brown J, Roberts MR. Differential contribution of beta-adrenergic receptors expressed on radiosensitive versus radioresistant cells to protection against inflammation and mortality in murine endotoxemia. Shock. 2009;32(5):541-547.
28. Ibrahim-zada ICG, Means R, Weller J, Rhee PM, Friese RS. Beta1-adrenergic antagonists in sepsis: survival benefit due to immunomodulation? Shock. 2013;39:P139.
29. Kenneth Kerut E., McIlwain E. F. and Plotnick G. D. (eds) (2007) Basics of Fluid Mechanics and Hemodynamic Equations, in Handbook of Echo-Doppler Interpretation, Second Edition, Blackwell Publishing, Oxford, UK. doi: 10.1002/9780470988435.ch3
30. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP, Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4(3): 249-264.
31. Ghosh D. TFD: the transcription factors database. Nucleic Acids Res. 1992;(Suppl 20):2091-2093.
32. Sutherland A, Thomas M, Brandon RA, Brandon RB, Lipman J, Tang B, McLean A, Pascoe R, Price G, Nguyen T, et al. Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. Crit Care. 2011;15(3):R149.
33. Berk JL, Hagen JF, Dunn JM. The role of beta adrenergic blockade in the treatment of septic shock. Surg Gynecol Obstet. 1970;130(6):1025-1034.
34. Rudiger A. Beta-block the septic heart. Crit Care Med. 2010;38(Suppl 10): S608-S612.
35. Arbabi S, Ahrns KS, Wahl WL, Hemmila MR, Wang SC, Brandt MM, Taheri PA. Beta-blocker use is associated with improved outcomes in adult burn patients. J Trauma. 2004;56(2):265-269; discussion 269-271.
36. Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med. 2001; 345(17):1223-1229.
37. Grisanti LA, Evanson J, Marchus E, Jorissen H, Woster AP, DeKrey W, Sauter ER, Combs CK, Porter JE. Pro-inflammatory responses in human monocytes are beta1-adrenergic receptor subtype dependent. Mol Immunol. 2010;47(6):1244-1254.
38. Mori K, Morisaki H, Yajima S, Suzuki T, Ishikawa A, Nakamura N, Innami Y, Takeda J. Beta-1 blocker improves survival of septic rats through preservation of gut barrier function. Intensive Care Med. 2011;37(11): 1849-1856.